Insider Transactions in Q1 2026 at Galectin Therapeutics Inc (GALT)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 06
2026
|
Joel Lewis President and CEO |
SELL
Open market or private sale
|
Direct |
37,698
-4.33%
|
$113,094
$3.58 P/Share
|
|
Jan 06
2026
|
Khurram Jamil Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,446
-100.0%
|
$64,338
$3.65 P/Share
|
|
Jan 06
2026
|
Jack W Callicutt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,354
-72.78%
|
$61,062
$3.67 P/Share
|
|
Jan 05
2026
|
Joel Lewis President and CEO |
SELL
Open market or private sale
|
Direct |
27,731
-3.09%
|
$83,193
$3.91 P/Share
|
|
Jan 05
2026
|
Khurram Jamil Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
25,499
-54.32%
|
$76,497
$3.9 P/Share
|
|
Jan 05
2026
|
Jack W Callicutt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,732
-47.92%
|
$77,196
$3.9 P/Share
|
|
Jan 02
2026
|
Joel Lewis President and CEO |
SELL
Open market or private sale
|
Direct |
18,571
-2.03%
|
$74,284
$4.2 P/Share
|
|
Jan 02
2026
|
Joel Lewis President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
84,000
+8.4%
|
-
|
|
Jan 02
2026
|
Khurram Jamil Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
13,055
-21.76%
|
$52,220
$4.2 P/Share
|
|
Jan 02
2026
|
Khurram Jamil Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+50.0%
|
-
|
|
Jan 02
2026
|
Jack W Callicutt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,914
-20.58%
|
$55,656
$4.2 P/Share
|
|
Jan 02
2026
|
Jack W Callicutt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+47.02%
|
-
|